New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Q2 2025 Earnings Call Transcript July 29, 2025 Alkermes plc beats earnings expectations. Reported EPS is $0.517, expectations ...

In the highly competitive biotech industry, only a few standout companies attract Wall Street’s attention. Among them, two ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...